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Background: Intracerebral hemorrhage (ICH) induces microglial activation and the release of inflammatory cytokines,
leading to inflammation in the brain. IRAK4, an essential component of the MyD88-dependent pathway, activates
subsets of divergent signaling pathways in inflammation.
Methods: In the experiment, microglia were stimulated with erythrocyte lysates, and then miR-367, IRAK4, NF-ĸB
activation and downstream proinflammatory mediator production were analyzed. In addition, inflammation, brain
edema, and neurological functions in ICH mice were also assessed.
Results: Here, we report that ICH downregulated miR-367 expression but upregulated IRAK4 expression in primary
microglia. We also demonstrate that miR-367 suppressed IRAK4 expression by directly binding its 3′-untranslated
region. MiR-367 inhibited NF-ĸB activation and downstream proinflammatory mediator production. Knocking down
IRAK4 in microglia significantly decreased the IRAK4 expression and inhibited the NF-ĸB activation and the downstream
production of proinflammatory mediators. In addition, our results indicate that miR-367 could inhibit expression of
proinflammatory cytokines, reduce brain edema, and improve neurological functions in ICH mice.
Conclusions: In conclusion, our study demonstrates that miR-367/IRAK4 pathway plays an important role in microglial
activation and neuroinflammation in ICH. Our finding also suggests that miR-367 might represent a potential
therapeutic target for ICH.
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Intracerebral hemorrhage (ICH) is a particularly devas-
tating form of stroke with high mortality and morbidity
[1–3]. Patients with ICH have poor prognosis, 80 % of
those survivors beyond the acute phase may suffer pro-
longed neurological deficits and brain atrophies [4–6].
Brain damage after ICH is caused not only by the mass
effect of hematoma but also by the secondary pathological
processes. ICH causes secondary injury through vari-
ous pathways, including the initiation of an acute* Correspondence: yangzhao5140@sohu.com
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species (ROS), and perihematomal edema [7–9].
The TLR/IL-1R superfamily mediates the innate immune
response mainly by upregulating the expression of inflam-
matory genes in multiple target cells [10–12]. A member
of the IL-1 receptor (IL-1R)-associated kinase (IRAK)
family, IRAK4, has been shown to play an essential role
in Toll-like receptor (TLR)-mediated signaling [13–15].
IRAK4 kinase inactive knockin mice have been shown
to be completely resistant to LPS- and CpG-induced
shock, due to impaired TLR-mediated induction of pro-
inflammatory cytokines and chemokines.
MicroRNAs (miRNAs) are key players in regulating
inflammatory response. Some miRNAs have anti-
inflammatory functions and serve as negative feedbackdistributed under the terms of the Creative Commons Attribution 4.0
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such as Toll-like receptor, interleukin (IL)-1β, or IL-13,
can stimulate the upregulation of miR-147, miR-146a, or
miR-21, respectively. These miRNAs either reduce inflam-
matory factor expression or suppress inflammatory re-
sponse [17–19].
Previously, we used a miRNA microarray to detect the
expression profiles of cellular miRNAs, and our unpublished
observations found that the expression level of miR-367
was significantly downregulated in microglia treated with
erythrocyte lysates. To further explore the potential target
proteins of miR-367, we utilized the bioinformatic tool,
TargetScan, and found that IRAK4 was the main target.
In the present study, we aimed to investigate whether
miR-367 was involved in the regulation of inflammatory
responses via IRAK4 in ICH. Our present data identified
that miR-367 was a crucial regulator of TLRs downstream
NF-κB signaling by direct targeting IRAK4. These results




Primary hippocampal microglia was isolated from glial
cultures prepared from newborn (less than 24 h old)
Sprague-Dawley (SD) rats (Laboratory Animal Center,
Chongqing Medical University, Chongqing, China). Glial
cells were cultured in 75 cm2 flasks for 14 days in
DMEM/F12 (Gibco BRL, Grand Island, NY, USA) sup-
plemented with 10 % FCS (Hyclone, Logan, UT, USA),
100 U/ml penicillin and 100 mg/ml streptomycin.
Microglia was isolated from primary mixed glial cell cul-
tures on day 10 by shaking the flasks overnight at 300 rpm
on a rotary shaker at 37 °C. The purity of the microglial
cultures was assessed as over 90 %, using a CD11b anti-
body (Santa Cruz, USA). Cells were cultured for 2 days be-
fore treatment. The Chongqing Medical Experimental
Animal Care Committee approved the protocol for this
study, and all animal experiments were conducted in ac-
cordance with the National Institutes of Health Guidelines
for the Care and Use of Laboratory Animals.
Preparation of erythrocyte lysates
Spleens were removed from SD rats. Single-cell suspen-
sions of splenocytes were prepared using stainless steel
mesh screens. And then, 1 × 105 splenocytes were incu-
bated with 1 ml red blood cell lysing solution for 20 min,
and centrifuged at 2000 rpm for 10 min. The supernatants
were utilized as erythrocyte lysates.
Cell treatment
Microglia (1 × 105) was stimulated with 10 μl PBS or
erythrocyte lysates for 48 h. After then, the supernatantswere removed and further analyzed for cytokine produc-
tion with ELISA.Real-time PCR
Total RNA was extracted from the microglia using TRIzol
reagent (Invitrogen, San Diego, CA, USA) in accordance
with the manufacturer’s instructions. Semi-quantitative
real-time PCR, using SYBR Green I, was conducted to
compare the relative expression levels of specific mRNAs.
The sequences of primers used were shown as follow-
ing: IRAK-4, 5′-GTCATGACCAGC CGAA TCGTG-3′
(forward), 5′-CAG ACA CT GGTCAGCAGCAGA-3′




(reverse); TNF-α, 5′-C GAG TG AC AAGCCT GTAGC -3′
(forward); 5′-TACTTGG GCAGAT TGACCTC A -3′
(reverse); GADPH, 5′-CAT GGTCTACATGTTCCAGT-3′
(forward); 5′-GGCTAAGCAGTTGGTGGT GC -3′ (reverse).
TaqMan miRNA assays (Applied Biosystems Inc.,
Carlsbad, CA, USA) were used to quantify mature miRNA
expression levels, in accordance with the manufacturer’s
protocol. For each of the selected miRNAs, real-time PCR
measurements were performed to obtain a mean CT value
for each sample. The CT values of the different samples
were compared using the 2-ΔΔCT method, and U6 expres-
sion levels were used as an internal reference as previous
methods [20]. All PCR experiments were done in triplicate
on an ABI system in 384-well plates using the TaqMan
Universal Master Mix II with the UNG kit. PCR primers
were obtained from Applied Biosystems. Each run in-
cluded water blanks and genomic DNA as negative con-
trols. Each run consisted of 35 cycles with miRNA levels
in samples without amplification signal considered zero.Western blotting analysis
Briefly, total protein was extracted from cultured cells
and quantified using a commercial bicinchoninic acid
(BCA) kit (BCA Protein Assay Kit; Pierce Biotechnology
Inc., Rockford, IL, USA) with BSA as the standard. Equal
amounts of protein from different cells were separated
by 10 % SDS-PAGE and transferred to a nitrocellulose
membrane (Bio-Rad, Hercules, CA, USA). The membrane
was blocked with 5 % non-fat milk, and incubated
with primary antibodies (IRAK4, NF-κB p65; Santa
Cruz, USA). The blots were then incubated for 2 h at
room temperature with horseradish peroxidase-conjugated
secondary antibodies in blocking buffer. Target pro-
teins were detected using an enhanced chemilumines-
cence kit (Amersham Pharmacia Biotech, Uppsala,
Sweden).
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Supernatants were measured by ELISA as specified by
the manufacturer. Microglia plated in 24-well plates was
cultured with anaerobic for 6 h. The culture supernatants
were aspirated and stored at −70 °C until assayed by
ELISA. The concentrations of IL-6, IL-1β, and TNF-α in
the stored media were measured using a sandwich ELISA
kit (R&D Systems).
Oligonucleotide transfection
The control RNA duplexes for the miRNA mimics and
the small interfering RNAs (siRNAs) were not homologous
to any mouse gene sequences. The siRNAs were synthe-
sized by targeting mouse IRAK4 transcripts. Oligonucleo-
tide transfection was performed with commercial reagents
(Lipofectamine 2000; Invitrogen Corp.). Each transfection
used 50 nmol/l of RNA duplexes.
Vector construction and luciferase reporter assays
To generate the miR-367 expression vector, the miR-367
gene was amplified from mouse genomic DNA and cloned
into the pcDNA3.0 vector (Invitrogen Corp.). The lucifer-
ase complexes were constructed by ligating oligonucleo-
tides containing the wild-type ( GUGCAAU) or mutated
putative target site (ACAUGGC) of the mouse IRAK4
3′-untranslated region (UTR) into the multi-cloning
site of the p-MIR luciferase reporter vector (Ambion
Inc., Austin, TX, USA). BV-2 cells were cotransfected
with 80 ng of the luciferase reporter plasmid, 40 ng of
the pRL-TKRenilla-luciferase plasmid (Promega Corp.,
Madison, WI, USA), and the indicated RNAs (final con-
centration 20 nmol/l). At 24 h, after the transfection,
the firefly and Renilla luciferase activities were measured
(Dual-Luciferase Reporter Assay; Promega Corp.). Each
transfection was repeated twice in triplicate.
ICH model
Briefly, mice were anesthetized with an intraperitoneal
injection of 400 mg/kg chloral hydrate and fixed on a
mouse stereotaxic frame (Stoelting). A 20 μl volume of
autologous nonanticoagulated blood was collected from
the tail vein of the mouse and then injected into the
caudate nucleus at 2 μl/min under stereotactic guidance
at the following coordinates relative to bregma: 0.8 mm
anterior, 2 mm left lateral, and 3.5 mm deep during a
period of 10 min The needle was held in place for
10 min after injection, and the microsyringe was pulled
out after the blood had coagulated. The craniotomy was
then sealed with bone wax, and the scalp was closed
with sutures. Body temperature was maintained at 37 °C
throughout the procedure, and the mice were given free
access to food and water after they woke up. The mice
that died because of anesthesia were excluded.Intracerebroventricular injection
The in vivo transfection was performed according to the
method described as follows: the stereotaxic coordinates
were 0.5 mm posterior and 1.0 mm lateral to bregma
and 2.5–3.0 mm ventral to the surface of the skull. The
miR-367 mimics or miR-367 control (2 μg/2 μl) were
added to 1.25 μl of Entranster™ in vivo transfection re-
agent. The solution was mixed gently, left for 15 min and
then injected intracerebroventricularly (i.c.v.) using a micro
syringe (Hamilton, NV, USA) under the guidance of the
stereotaxic instrument (RWD Life Science).
Evaluation of neurological scores
The neurological scores were determined by neurological
severity scores, a composite of motor, sensory, reflex, and
balance tests according to the reference [21]. And the tim-
ing of performing behavioral experiments was 48 h after
blood infusion. Neurological function was graded on a
scale of 1 to 18; a score of 1 point is awarded for the in-
ability to perform the test or for the lack of a tested reflex.
The higher the score, the more severe the injury (normal
score 2–3, maximal deficit score 18).
Brain water content measurement
Brain water content was measured in mouse cerebral tis-
sues after ICH. Briefly, mice were randomly sampled from
each group and anesthetized by intraperitoneal injection
with chloral hydrate (n = 5). Next, the cerebral tissues
were removed, and the surface water on the cerebral tis-
sues was blotted with filter paper. Brain samples were
immediately weighed on an electric analytic balance to
obtain the wet weight and then dried at 100 °C for 24 h
to obtain the dry weight. Brain water content was cal-
culated using the following formula: brain water con-
tent (%) = (wet weight − dry weight)/wet weight × 100 %.
Statistical analysis
The statistical significance of differential findings between
experimental groups and controls were determined by
ANOVA and post-hoc analysis, and considered significant
if P < 0.05.
Results
Erythrocyte lysates upregulated IRAK4 expression but
downregulated miR-367 expression in microglia
We measured IRAK4 mRNA and protein expression of
microglia 48 h after erythrocyte lysates or PBS treatment.
We found that IRAK4 mRNA and protein expression
increased after erythrocyte lysates treatment. On the
contrary, miR-367 expression significantly decreased after
erythrocyte lysates treatment (Fig. 1). These results dem-
onstrated that miR-367 and IRAK4 expression of micro-
glia have an inverse correlation after erythrocyte lysates
treatment.
Fig. 1 Erythrocyte lysates upregulated IRAK4 expression but
downregulated miR-367 expression in microglia. Microglia (1 × 105)
was stimulated with 10 μl PBS or erythrocyte lysates for 48 h. a IRAK4
and miR-367 mRNA expression levels were evaluated by quantitative
RT-PCR. b IRAK4 protein expression levels were evaluated by western
blots. Experiments performed in triplicate showed consistent results.
Data are presented as the mean ± SD of three independent
experiments. *P < 0.05
Fig. 2 miR-367 regulates IRAK4 expression in microglia. a Microglia
was transfected with miR-367 mimics or miR-367 control. After 24 h,
cells were harvested, and miR-367 expression was evaluated by
RT-PCR. b Microglia was transfected with miR-367 mimics or miR-367
control, and then was treated with PBS or erythrocyte lysates. After
48 h, cells were harvested, and IRAK4 mRNA and protein expression
were evaluated by RT-PCR and western blots. Experiments performed
in triplicate showed consistent results. Data are presented as the
mean ± SD of three independent experiments. *P < 0.05
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To detect the relationship of miR-367 and IRAK4, we
transfected microglia with miR-367 mimics or miR-367
control. We found that transfection of miR-367 im-
proved miR-367 mRNA expression (Fig. 2a). We further
transfected microglia with miR-367 mimics or miR-367
control, and then treated the microglia with erythrocyte
lysates. Microglia transfected with miR-367 had dramat-
ically reduced IRAK4 expression (Fig. 2b), whichsuggests that miR-367 inhibits erythrocyte lysate-induced
IRAK4 expression in microglia.IRAK4 is a direct target of miR-367 in microglia
We hypothesized that IRAK4 is a direct target of miR-367
in microglia. The 3′-UTR of IRAK4 mRNA contains a
putative miR-367 target sequence based on the target pre-
diction program TargetScan (www.targetscan.org) (Fig. 3a).
We tested this interaction using a Dual-Luciferase re-
porter system. Co-expression with miR-367 mimics sig-
nificantly suppressed the activity of a firefly luciferase
reporter containing wild-type IRAK4 3′-UTR but had
no effect on a reporter with a mutated IRAK4 3′-UTR
(Fig. 3b). These results indicate that miR-367 likely
Fig. 3 IRAK4 is a direct target of miR-367 in microglia. a A IRAK4 3′UTR fragment containing wild-type or mutant miR-367-binding sites was cloned
downstream of the luciferase reporter gene. The region of the IRAK4 mRNA 3′UTR predicted to be targeted by miR-367 as indicated. b Luciferase
activity assays using reporters with wild-type or mutant IRAK4 3′UTRs were performed after cotransfection with miR-367 mimics or control in
microglia. The luciferase activity of the control transfection in each experiment was used to normalize the data, and the luciferase activity of
the control transfection was set equal to 1. Experiments performed in triplicate showed consistent results. Data are presented as the mean ± SD of
three independent experiments. *P < 0.05
Fig. 4 miR-367 inhibited NF-κB activation and the downstream production of proinflammatory mediators in microglia. Microglia was transfected
with miR-367 mimics or miR-367 control. And then, microglia (1 × 105) was stimulated with PBS or erythrocyte lysates for 48 h. a NF-κB p65 mRNA
and protein expression were analyzed using by RT-PCR and western blots. b IL-6, IL-1β and TNF-α mRNA and protein expression were evaluated
by RT-PCR and ELISA. Experiments performed in triplicate showed consistent results. Data are presented as the mean ± SD of three independent
experiments. *P < 0.05
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sites in the IRAK4 3′-UTR.
miR-367 inhibited NF-κB activation and proinflammatory
mediators production
IRAK4 encodes a kinase that activates NF-κB in both
the Toll-like receptor (TLR) and T-cell receptor (TCR)
signaling pathways, which induces the production of vari-
ous proinflammatory mediators. We detected the effects
of miR-367 on the NF-κB pathway of erythrocyte lysate-
treated microglia. The results demonstrated that upregu-
lated miR-367 attenuated NF-κB p65 mRNA and protein
levels in the nuclei of erythrocyte lysate-treated microgliaFig. 5 IRAK4 mediated the suppressed inflammatory response induced by m
efficiency of siRNAs against IRAK4. Microglia was transfected with scramble siR
IRAK4 protein expression was analyzed using western blots. b Microglia was t
or erythrocyte lysates. After 48 h, IRAK4 and NF-κB p65 protein expression
scramble siRNA or IRAK4 siRNA and then exposed to PBS or erythrocyte l
were evaluated by RT-PCR and ELISA. Experiments performed in triplicate
three independent experiments. *P < 0.05(Fig. 4a). In addition, we also found that upregulated
miR-367 attenuated inflammatory mediator expression
of erythrocyte lysate-treated microglia (Fig. 4b).
miR-367 attenuated inflammatory response of microglia
via IRAK4
To identify whether miR-367 attenuated inflammatory
response of microglia via IRAK4, we utilized siRNA to
inhibit IRAK4 expression and observed the inflammatory
response of microglia. We found that IRAK4 siRNA
clearly decreased IRAK4 protein expression. However,
scramble siRNA had no similar effect (Fig. 5a, b). In
addition, inhibition of IRAK4 significantly decreasediR-367 in erythrocyte lysate-treated microglia. a Detection of the inhibition
NA or IRAK4 siRNA and then exposed to erythrocyte lysates. After 48 h,
ransfected with scramble siRNA or IRAK4 siRNA and then exposed to PBS
were analyzed using western blots. c Microglia was transfected with
ysates. After 48 h, IL-6, IL-1β, and TNF-α mRNA and protein expression
showed consistent results. Data are presented as the mean ± SD of
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production of proinflammatory mediators. However,
scramble siRNA had no similar effect (Fig. 5b, c). These
data demonstrated that miR-367 attenuated inflamma-
tory response of microglia via IRAK4.
miR-367 inhibits inflammation response in vivo
To identify whether miR-367 could inhibit inflammation
response in vivo, we analyzed IRAK4, NF-κB p65, and
inflammatory cytokines expression in mice after ICH.
We found that administration of miR-367 significantly
improved the miR-367 level in vivo, and miR-367 could
significantly inhibit IRAK4, NF-κB p65, IL-6, IL-1β, andFig. 6 miR-367 inhibited inflammation response and improved neurological
miR-367 mimics or miR-367 control 10 min after ICH and sacrificed 48 h after
assayed by qRT-PCR assay. b Western blotting was used to evaluate IRAK4, NF
water content of mice was analyzed. d The neurological deficit tests were de
reflex, and balance tests. Neurological function was graded on a scale of 1 to
consistent results. Data are presented as the mean ± SD of three independenTNF-α expression in brain tissues after ICH (Fig. 6a, b).
These data showed that miR-367 could inhibit inflam-
mation response in vivo.
miR-367 reduces brain damage in ICH
In mice subjected to ICH for 48 h, water content in mice
brains and neurological injury were observed. The re-
sults demonstrated that the water content in mice brains
and neurological injury significantly increased compared
to sham-operated animals. To determine the contribu-
tion of miR-367 to neurological function, i.c.v. injection
of miR-367 control or mimics were administered 10 min
after ICH. We found that administration of miR-367injury in vivo. Mice were received an intracerebral ventricular injection of
ICH. The brains were dissected. a The mRNA levels of miR-367 were
-κB p65, IL-6, IL-1β, and TNF-α expression of brain tissues. c The cerebral
termined by neurological severity scores, a composite of motor, sensory,
18, and repeated three times. Experiments performed in triplicate showed
t experiments. *P < 0.05
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(Fig. 6c, d). These analyses showed that miR-367 could
ameliorate the neurological symptoms and improve brain
function after ICH.
Discussion
ICH is a common and devastating cerebral disease with
a higher morbidity and mortality than ischemic stroke
[22–24]. ICH-induced brain injury involves multiple
mechanisms. The primary injury is due to the disruption
of adjacent tissue and mass effect. The secondary brain
damage occurs as a result of hematoma, inflammation,
local release of ROS, and perihematomal edema [25–27].
miRNAs are a recently discovered class of small, non-
coding RNAs with gene-regulating functions. It has been
shown that miRNAs regulate the expression of protein-
coding genes at the post-transcriptional level through
imperfect base pairing with the 3′-UTRs of their target
mRNAs [28–30]. Much evidence suggests that miRNA
dysregulation may contribute to many types of human
disease, including neuronal disorders [31–33]. However,
the miRNA expression profiles of microglia after ICH
are very limited. Although microglial activation is con-
sidered to be a hallmark of neuroinflammation, whether
the expression of proinflammatory cytokines is regulated
by miRNAs during microglial activation is still known.
Previous studies showed that the recognition of TLRs
to pathogen-associated molecular patterns (PAMPs) could
initiate protective immune responses. Studies of TLR
signaling have also demonstrated that ligation of TLRs
induced the recruitment and activation of IRAK4 [34–36].
Upon binding of a TLR/MyD88 complex, IRAK4 can act
as a kinase that functions upstream of and phosphorylates
IRAK. Then, the phosphorylated IRAK mediates the re-
cruitment of TRAF6 to the receptor complex, resulting in
transcription of pro-inflammatory cytokines [37–39].
Previously, we found that the expression level of
miR-367 was significantly downregulated in microglia
treated with erythrocyte lysates. Related studies showed
that miR-367 promoted pancreatic cancer invasion in vitro
and metastasis in vivo through downregulating Smad7
[40]. The results suggest that miR-367 may be a promising
therapeutic target for the treatment of human pancreatic
cancer. In addition, increasing evidence suggests that
several microRNAs (miRNAs) are involved in early em-
bryonic development and embryonic stem cell formation,
known as embryonic stem cell (ESC)-specific miRNAs.
The development of this miR-302/367-mediated iPSC
(termed mirPSC) may provide tools to deal with the
obstacles facing some current iPSC reprogramming
methods [41].
In this study, we identified an inverse relationship bet-
ween miR-367 and IRAK4 expression. The 3′UTR of
IRAK4 mRNA contained conserved miR-367 bindingsites, and we showed that miR-367 directly regulated
IRAK4 expression through these 3′UTR sites. Our results
indicate that miR-367 downregulation leads to increased
IRAK4 expression of microglia after ICH.
We further detected the effects of miR-367 on the
NF-κB pathway of erythrocyte lysate-treated microglia.
We found that upregulated miR-367 attenuated NF-κB
and inflammatory mediator expression of erythrocyte lysate-
treated microglia. In addition, we demonstrated that
inhibition of IRAK4 significantly decreased NF-κB activa-
tion and the downstream production of proinflammatory
mediators. These data demonstrated that miR-367 attenu-
ated inflammatory response of microglia via IRAK4.
Lastly, we found that over-expression of miR-367
significantly inhibited IL-6, IL-1β, and TNF-α expression
in brain tissues, reduced water content and neurological
injury after ICH. These data showed that miR-367 could
inhibit inflammation response in vivo, meliorate the neuro-
logical symptoms, and improve brain function after ICH.
Conclusion
In conclusion, we identified a strong correlation between
miR-367 and IRAK4, and the effect of miR-367 on micro-
glial activation after ICH. Therefore, the miR-367 repre-
sents a potential therapeutic target for ICH.
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